← Leaderboards
Joel M. Linden
University Of Virginia Charlottesville
$14,399,863
Attributed
$26,337,290
Total exposure
9
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.6M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$32,720,149 · 10
By mechanism
R01$12,341,619 · 4
P50$10,797,309 · 1
P01$7,736,582 · 3
RC2$1,817,442 · 1
U2C$27,197 · 1
Top collaborators
- David G. Nathan12 shared
- Joshua Jeffrey Field10 shared
- Jonathan R Lindner5 shared
- Donna S. Neuberg4 shared
- Klaus F. Ley2 shared
Most similar at University Of Virginia Charlottesville
Same institution · by research overlap
- Kambiz Kalantarinia$755,340
- Irving L Kron$20,314,863
- Victor E Laubach$15,022,296
- Victor H. Engelhard$22,896,814
- Umesh S Deshmukh$7,411,901
Others in their field
Top investigators on “Adenosine”
- Chuan He · University Of Chicago$25,386,171
- Raymond C Stevens · University Of Calif-Lawrenc Berkeley Lab$17,634,454
- Joshua A Boyce · Brigham And Women'S Hospital$14,914,539
- Bruce Neil Cronstein · New York University School Of Medicine$14,895,406
- Kazuko Nishikura · University Of Pennsylvania$14,781,272
- Samie R Jaffrey · Weill Medical College Of Cornell Univ$13,696,773
Research focus
AdenosineReceptorCellsAgonistResponseInflammationTissuesInjuryMacrophageResearch PersonnelIschemiaMediatingNeutrophilReceptor ExpressionLeukocytesDoseReperfusion InjuryAffectBloodInflammatoryUniversitiesProgramsAdenosine A2a ReceptorLigands
Grant awards (52)
IGNITE KUH Professional Development Core$5,814
U2C · FY2025 · DK · contact PI
IGNITE KUH Professional Development Core$5,233
U2C · FY2024 · DK · contact PI
IGNITE KUH Professional Development Core$5,814
U2C · FY2023 · DK · contact PI
IGNITE KUH Professional Development Core$5,426
U2C · FY2022 · DK · contact PI
IGNITE KUH Professional Development Core$4,910
U2C · FY2021 · DK · contact PI
A Controlled Clinical Trial of Regadenoson in Sickle Cell Anemia$2,004,198
P50 · FY2016 · HL
Biomarkers of Inflammation and Vaso-occlusion in Sickle Cell Disease$799,323
R01 · FY2016 · HL · contact PI
A Controlled Clinical Trial of Regadenoson in Sickle Cell Anemia$2,108,843
P50 · FY2015 · HL
Biomarkers of Inflammation and Vaso-occlusion in Sickle Cell Disease$787,224
R01 · FY2015 · HL · contact PI
A Controlled Clinical Trial of Regadenoson in Sickle Cell Anemia$2,181,100
P50 · FY2014 · HL
Biomarkers of Inflammation and Vaso-occlusion in Sickle Cell Disease$788,408
R01 · FY2014 · HL · contact PI
Lymphocyte Activation in Sickle Cell Lung Disease$450,677
R01 · FY2014 · HL · contact PI
A Controlled Clinical Trial of Regadenoson in Sickle Cell Anemia$2,220,754
P50 · FY2013 · HL
Biomarkers of Inflammation and Vaso-occlusion in Sickle Cell Disease$770,409
R01 · FY2013 · HL · contact PI
Lymphocyte Activation in Sickle Cell Lung Disease$438,013
R01 · FY2013 · HL · contact PI
A Controlled Clinical Trial of Regadenoson in Sickle Cell Anemia$2,282,414
P50 · FY2012 · HL
Biomarkers of Inflammation and Vaso-occlusion in Sickle Cell Disease$904,227
R01 · FY2012 · HL · contact PI
Lymphocyte Activation in Sickle Cell Lung Disease$460,316
R01 · FY2012 · HL · contact PI
Lymphocyte Activation in Sickle Cell Lung Disease$465,178
R01 · FY2011 · HL · contact PI
CTRIP: Treatment of Sickle Cell Crisis with inhibitors of NKT cell activation$948,786
RC2 · FY2010 · HL
Lymphocyte Activation in Sickle Cell Lung Disease$487,609
R01 · FY2010 · HL · contact PI
CTRIP: Treatment of Sickle Cell Crisis with inhibitors of NKT cell activation$868,656
RC2 · FY2009 · HL
Allosteric Enhancement of Adenosine Receptors$340,946
R01 · FY2009 · HL · contact PI
Purification & Characterization of Adenosine Receptors$318,058
R01 · FY2009 · HL · contact PI
Purification & Characterization of Adenosine Receptors$47,560
R01 · FY2009 · HL · contact PI
Allosteric Enhancement of Adenosine Receptors$26,820
R01 · FY2009 · HL · contact PI
Allosteric Enhancement of Adenosine Receptors$367,766
R01 · FY2008 · HL · contact PI
Purification & Characterization of Adenosine Receptors$365,681
R01 · FY2008 · HL · contact PI
Molecular and Cellular Targets of Adenosine in Lung$332,774
P01 · FY2008 · HL · contact PI
ROLE OF INFLAMMATION IN PULMONARY INJURY$1,595,687
P01 · FY2007 · HL · contact PI
Allosteric Enhancement of Adenosine Receptors$367,766
R01 · FY2007 · HL · contact PI
Purification and Characterization of Adenosine Receptors$365,741
R01 · FY2007 · HL · contact PI
Molecular and Cellular Targets of Adenosine in Lung$329,673
P01 · FY2007 · HL · contact PI
ROLE OF INFLAMMATION IN PULMONARY INJURY$1,595,477
P01 · FY2006 · HL · contact PI
Allosteric Enhancement of Adenosine Receptors$380,000
R01 · FY2006 · HL · contact PI
Purification & Characterization of Adenosine Receptors$377,956
R01 · FY2006 · HL · contact PI
Molecular and Cellular Targets of Adenosine in Lung$217,024
P01 · FY2006 · HL · contact PI
ROLE OF INFLAMMATION IN PULMONARY INJURY$1,585,443
P01 · FY2005 · HL
Molecular and Cellular Targets of Adenosine in Lung$210,702
P01 · FY2005 · HL
ROLE OF INFLAMMATION IN PULMONARY INJURY$1,606,252
P01 · FY2004 · HL
Purification and Characterization of Adenosine Receptors$331,286
R01 · FY2004 · HL
ALLOSTERIC ENHANCEMENT OF ADENOSINE RECEPTORS$297,000
R01 · FY2004 · HL
Molecular and Cellular Targets of Adenosine in Lung$229,567
P01 · FY2004 · HL
Administrative Core$33,983
P01 · FY2004 · HL
Purification and Characterization of Adenosine Receptors$331,286
R01 · FY2003 · HL
ALLOSTERIC ENHANCEMENT OF ADENOSINE RECEPTORS$297,000
R01 · FY2003 · HL
Purification and Characterization of Adenosine Receptors$331,286
R01 · FY2002 · HL
ALLOSTERIC ENHANCEMENT OF ADENOSINE RECEPTORS$297,000
R01 · FY2002 · HL
Purification and Characterization of Adenosine Receptors$331,286
R01 · FY2001 · HL
ALLOSTERIC ENHANCEMENT OF ADENOSINE RECEPTORS$260,000
R01 · FY2001 · HL
PURIFICATION AND CHARACTERIZATION OF ADENOSINE RECEPTORS$283,797
R01 · FY2000 · HL
ALLOSTERIC ENHANCEMENT OF ADENOSINE RECEPTORS$272,000
R01 · FY2000 · HL